Barclays’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Barclays’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-23,471	Closed	-$912K	–	7405
2017 Q3	$912K	Buy	23,471 +22,400	+2,092%	+$824K	﹤0.01%	3088
2017 Q2	$32K	Buy	1,071 +35	+3%	+$907	﹤0.01%	5587
2017 Q1	$28K	Sell	1,036 -3,500	-77%	-$86.7K	﹤0.01%	5658
2016 Q4	$101K	Buy	4,536 +1,144	+34%	+$21.4K	﹤0.01%	4736
2016 Q3	$62K	Buy	3,392 +3,112	+1,111%	+$53.9K	﹤0.01%	4864
2016 Q2	$5K	Buy	280 +194	+226%	+$3.27K	﹤0.01%	5771
2016 Q1	$1K	Sell	86 -4,882	-98%	-$65.9K	﹤0.01%	6097
2015 Q4	$84K	Buy	+4,968	New	+$96.8K	﹤0.01%	4520

Other funds holding NDRM

VOAM

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Barclays's NDRM Position: Q4 2017 in Review

Barclays sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 23,471 shares — an estimated $912K sold.

Barclays first reported a position in NDRM in Q4 2015 and held it in 8 quarters. The position peaked at $912K in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

Barclays reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Barclays sold 23,471 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $912K.
Barclays first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 8 quarters.
Barclays's NeuroDerm Ltd. Ordinary Shares position peaked at $912K in Q3 2017.
5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.